Separately, while it's true that Bluebird may struggle with competing for market share, it has other projects in the pipeline that could hit the market before CTX001. In particular its Lenti-D gene therapy for cerebral adrenoleukodystrophy is in phase 3 clinical trials, and its ide-cel gene therapy for treatment-resistant multiple myeloma recently scored a key approval from regulators. Success in either of these projects would relieve the looming competitive pressure on its revenue, not to mention restoring some confidence in its stock.